Bio Protocol BIO · perps

BIO's derivatives market shows modest positioning with an open interest of $14.4M and benign leverage conditions overall. The aggregated funding rate stands at 9.93%, currently sitting at the 61st percentile of its 90-day range—elevated relative to recent history but not at extremes. This suggests longs are paying shorts at a meaningfully positive clip, indicating some crowding on the long side, though the market has not shifted into the most stretched territory it has seen over the prior quarter.

Deleveraging has been gradual. Open interest declined 0.2% over the past day and 5.2% over the past week, suggesting positions are closing or traders are reducing exposure at a measured pace rather than in panic. The liquidation imbalance of -1.00 indicates a pronounced skew toward short liquidations over the 24-hour period, which is consistent with a market where long leverage faces pressure but shorts are being cleared out more aggressively.

The leverage risk score of 5 points to very low systemic fragility in BIO's perpetual-futures ecosystem. Combined with the modest notional size and gradual deleveraging trend, the market appears structurally sound with minimal crowding or cascade risk. The elevated funding rate relative to recent norms warrants monitoring, but overall positioning does not signal acute instability.